Krish Krishnan compensation by year
Krystal Biotech Summary Compensation Table · all 9 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Salary | $69,444 | $469,994 | $365,725 | $498,220 | $580,997 | $644,845 | $733,333 | $801,667 | $846,167 |
| Bonus | $0 | $235,000 | $0 | $254,153 | $309,535 | $325,000 | $487,500 | $714,560 | $682,400 |
| Stock awards | $0 | $0 | $0 | $0 | $3,218,708 | $0 | $2,047,750 | $13,953,625 | $4,104,825 |
| Option awards | $0 | $0 | $0 | $0 | $3,123,339 | $2,189,636 | $2,852,511 | $0 | $4,675,093 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $0 | $0 | $0 | $118,400 | $96,986 | $102,800 | $133,800 | $134,000 |
| Total | $69,444 | $704,994 | $365,725 | $752,373 | $7,350,978 | $3,256,467 | $6,223,894 | $15,603,652 | $10,442,485 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Krystal Biotech, Inc. DEF 14A filed April 3, 2026, accession 0001711279-26-000036, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Krystal Biotech, Inc. filed document, accession 0001711279-26-000036. Every figure is read from that document and cited to the page and table it appears in. Filed April 3, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 26,250 | $6,471,675 | — |
| RSU | 22,900 | $5,645,766 | — |
| Option | 12,500 | — | $63.55 |
| Option | 25,000 | — | $81.91 |
| Option | 39,300 | — | $179.25 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Krystal Biotech, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
24 Form 4 lines since the FY2025 proxy (filed April 3, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-04 | Sale | 10b5-1 | 520 | $354.54 | 1,372,023 |
| 2026-09-04 | Sale | 10b5-1 | 2,029 | $355.57 | 1,369,994 |
| 2026-09-04 | Sale | 10b5-1 | 3,297 | $356.37 | 1,366,697 |
| 2026-09-04 | Sale | 10b5-1 | 2,266 | $360.46 | 1,353,950 |
| 2026-09-04 | Sale | 10b5-1 | 1,214 | $361.61 | 1,352,736 |
| 2026-09-04 | Sale | 10b5-1 | 1,358 | $364.48 | 1,348,795 |
| 2026-09-04 | Sale | 10b5-1 | 573 | $363.34 | 1,350,153 |
| 2026-09-04 | Sale | 10b5-1 | 3,981 | $357.57 | 1,362,716 |
The 8 most recent of 24 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Krystal Biotech’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Krish Krishnan · this page | Chairman, President, and Chief Executive Officer | $10,442,485 |
| Suma Krishnan | Founder and President, R&D | $6,948,401 |
| Kathryn Romano | EVP & Chief Accounting Officer | $2,258,697 |
Board service
Krystal Biotech board · FY2023–FY2025How this board is paid
Company policy: Krystal Biotech pays directors a $50,000 cash retainer and $410,972 in equity. As stated in Krystal Biotech's FY2025 proxy.
Committees
Commercial Advisory Committee (Chair)
The full Krystal Biotech compensation record
free company briefThis page is one person within Krystal Biotech's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Krystal Biotech proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Krystal Biotech's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Krystal Biotech's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order KRYS
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.